On January 1, Pune-based Serum Institute's Covishield vaccine was granted permission for restricted use, while Bharat Biotech's Covaxin got a similar approval the next day with certain other riders. With two vaccines now being greenlighted for restricted use, the four high-risk priority groups, beginning with frontline health-care workers, will soon begin getting vaccinated. Nearly 300 million people belonging to the four priority groups are to be vaccinated with either of the two vaccines for free. The Ahmedabad-based Zydus Cadilla only recently got the regulatory permission to carry out phase-3 trial and has to begin the recruitment, while the Hyderabad-based Biological E is yet to reach that stage. It is unclear if Dr. Reddy's Laboratory has completed enrolment for phase-3. Challenges in recruiting In a webinar hosted by DBT on December 31, Krishna Mohan, Executive Director of Bharat Biotech, had mentioned about the challenges in recruiting participants for phase-3 trial, as many felt they had only a 50% chance of getting the candidate vaccine. The news about vaccines soon becoming available made the recruitment even more challenging. Pankaj Patel, Chairman of Zydus Cadilla said during the webinar that he anticipates difficulties in quick recruitment of volunteers but not with recruitment per… Read full this story
- Bucking FDA, Peter Thiel funds “patently unethical” herpes vaccine trial
- Building a better flu vaccine -- one you don't have to get every year
- India gang-rape trial begins as father urges hangings
- India vs South Africa: Amol Muzumdar appointed South Africa batting coach for India series
- New Maharashtra govt’s challenge: Farmers in drought-prone Vidarbha reel, this time from excess rain
- How voters in constituencies where Shiv Sena fought NCP-Congress see the new alliance
- India pivotal to global fightback against AIDS, says chief of vaccine initiative
- The end of the flu jab? Scientists create a stick-on patch which may protect against the viral illness as effectively as the traditional vaccine
- Vaccines Are Hard to Transport to the Regions That Need Them Most. Solar-Powered Fridges Fix That.
- Washington Sundar re-emerges as India's specialist new-ball spinner
Coronavirus | New challenges for COVID-19 vaccine trials in India have 332 words, post on www.thehindu.com at January 9, 2021. This is cached page on wBlogs. If you want remove this page, please contact us.